These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 34342766)

  • 1. Outcomes of Stage I and II Breast Cancer with Nodal Micrometastases Treated with Mastectomy without Axillary Therapy.
    Lim SZ; Kusumawidjaja G; Mohd Ishak HM; Tan BKT; Tan SY; Hamzah JL; Madhukumar P; Yong WS; Wong CY; Sim Y; Lim GH; Lim SH; Tan SM; Wong FY; Tan VKM
    Breast Cancer Res Treat; 2021 Oct; 189(3):837-843. PubMed ID: 34342766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is axillary lymph node dissection necessary after sentinel lymph node biopsy in patients with mastectomy and pathological N1 breast cancer?
    Fu Y; Chung D; Cao MA; Apple S; Chang H
    Ann Surg Oncol; 2014 Dec; 21(13):4109-23. PubMed ID: 25081336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of axillary lymph node dissection after sentinel lymph node biopsy on overall survival in patients with T1 or T2 node-positive breast cancer: report from the Korean Breast Cancer Society.
    Park HS; Chae BJ; Song BJ; Jung SS; Han W; Nam SJ; Youn HJ; Ko BK; Kim DW;
    Ann Surg Oncol; 2014 Apr; 21(4):1231-6. PubMed ID: 24318094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Axillary Micrometastases and Isolated Tumor Cells Are Not an Indication for Post-mastectomy Radiotherapy in Stage 1 and 2 Breast Cancer.
    Mamtani A; Patil S; Stempel M; Morrow M
    Ann Surg Oncol; 2017 Aug; 24(8):2182-2188. PubMed ID: 28429197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-mastectomy Radiation Therapy in Breast Cancer Patients with Nodal Micrometastases.
    Wu SP; Tam M; Shaikh F; Lee A; Chun J; Schnabel F; Guth A; Adams S; Schreiber D; Oh C; Gerber NK
    Ann Surg Oncol; 2018 Sep; 25(9):2620-2631. PubMed ID: 29987606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database.
    Yi M; Giordano SH; Meric-Bernstam F; Mittendorf EA; Kuerer HM; Hwang RF; Bedrosian I; Rourke L; Hunt KK
    Ann Surg Oncol; 2010 Oct; 17 Suppl 3(0 3):343-51. PubMed ID: 20853057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Axillary treatment for operable primary breast cancer.
    Bromham N; Schmidt-Hansen M; Astin M; Hasler E; Reed MW
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004561. PubMed ID: 28052186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer.
    Bilimoria KY; Bentrem DJ; Hansen NM; Bethke KP; Rademaker AW; Ko CY; Winchester DP; Winchester DJ
    J Clin Oncol; 2009 Jun; 27(18):2946-53. PubMed ID: 19364968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncological Safety of Skipping Axillary Lymph Node Dissection in Patients with Clinical N0, Sentinel Node-Positive Breast Cancer Undergoing Total Mastectomy.
    Chun JW; Kang E; Kim HK; Lee HB; Moon HG; Lee JW; Han W
    Ann Surg Oncol; 2024 May; 31(5):3168-3176. PubMed ID: 38368292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sentinel lymph node biopsy following previous axillary surgery in recurrent breast cancer.
    Sávolt Á; Cserni G; Lázár G; Maráz R; Kelemen P; Kovács E; Győrffy B; Udvarhelyi N; Vörös A; Ormándi K; Mátrai Z
    Eur J Surg Oncol; 2019 Oct; 45(10):1835-1838. PubMed ID: 31126680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of axillary dissection in women with invasive breast cancer who do not fit the Z0011 ACOSOG trial because of three or more metastatic sentinel lymph nodes.
    Bonneau C; Hequet D; Estevez JP; Pouget N; Rouzier R
    Eur J Surg Oncol; 2015 Aug; 41(8):998-1004. PubMed ID: 25986854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection.
    Schulze T; Mucke J; Markwardt J; Schlag PM; Bembenek A
    J Surg Oncol; 2006 Feb; 93(2):109-19. PubMed ID: 16425290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer hormone receptor negativity, triple-negative type, mastectomy and not receiving adjuvant radiotherapy were associated with axillary recurrence after sentinel lymph node biopsy.
    Sekine C; Nakano S; Mibu A; Otsuka M; Oinuma T; Takeyama H
    Asian J Surg; 2020 Jan; 43(1):148-153. PubMed ID: 31153730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in axillary treatment for breast cancer patients undergoing sentinel lymph node biopsy as determined by a questionnaire from the Japanese Breast Cancer Society.
    Imoto S; Yamauchi C; Komoike Y; Tsugawa K; Yotsumoto D; Wada N; Ueno T; Oba MS; Shien T; Sugae S; Tsuda H; Yoneyama K
    Breast Cancer; 2017 May; 24(3):427-432. PubMed ID: 27553957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of T Stages on the Choice of Axillary Evaluation Modality in Breast Cancer Patients With 1-2 Sentinel Lymph Node Metastases.
    Liu D; Chang L; Zhao X; Dai L; Cui H; Liu P; Zhai Z; Wu H; Ma X; Kang H
    Clin Breast Cancer; 2024 Jun; 24(4):e232-e243.e1. PubMed ID: 38368246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Axilla lymph node dissection can be safely omitted in patients with 1-2 positive sentinel nodes receiving mastectomy: a large multi-institutional study and a systemic meta-analysis.
    Gao W; Lu S; Zeng Y; Chen X; Shen K
    Breast Cancer Res Treat; 2022 Nov; 196(1):129-141. PubMed ID: 36076127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcome in patients with nodal-positive breast cancer treated with sentinel lymph node biopsy alone after neoadjuvant chemotherapy.
    Lim SZ; Yoo TK; Lee SB; Kim J; Chung IY; Ko BS; Lee JW; Son BH; Ahn SH; Kim S; Kim HJ
    Breast Cancer Res Treat; 2024 Jan; 203(1):95-102. PubMed ID: 37796365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer: guiding a more selective axillary approach.
    Damin AP; Zancan M; Melo MP; Biazus JV
    Breast Cancer Res Treat; 2021 Apr; 186(2):527-534. PubMed ID: 33165710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of completion axillary dissection for patients with cT1-2N0 breast cancer undergoing total mastectomy with positive sentinel lymph nodes.
    Schwieger L; Postlewait LM; Subhedar PD; Geng F; Liu Y; Gillespie T; Arciero CA
    J Surg Oncol; 2024 Mar; 129(3):468-480. PubMed ID: 37955191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Axillary management and long-term oncologic outcomes in breast cancer patients with clinical N1 disease treated with neoadjuvant chemotherapy.
    Sparger CC; Hernandez AE; Rojas KE; Khan K; Halfteck GG; Möller M; Avisar E; Goel N; Crystal JS; Kesmodel SB
    World J Surg Oncol; 2024 Jul; 22(1):199. PubMed ID: 39075403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.